Innovation breakthrough, stable performance - CellXpress.ai helps organoids achieve high-quality cultivation and extensive validation

About Us

Meigu Molecular Instrument (Shanghai) Co., Ltd

E-mail
info.china@moldev.com
Phone
Address
5th Floor, Building 1, No. 518 Fuquan North Road, Changning District, Shanghai

Date: 2025-09-15Read: 0

In the field of biomedicine, organoids, as important tools for disease modeling, drug screening, and regenerative medicine, are entering a critical stage of transitioning from laboratory to industrial applications.

With the increasing recognition of the application of organoid models in drug screening and toxicity testing by the FDA, standardized and large-scale cultivation has become an urgent need in the industry.Meigu Molecular keeps up with the forefront of technology and launches CellXpress.ai solution for efficient cultivation and quality control of in vitro models, especially organoidsBy utilizing machine learning to autonomously manage liquid exchange, plate laying, passage, organoid growth quality control, endpoint detection, and complex image analysis, the automation of the entire long-term and complex organoid culture process can be achieved. Assist users in achieving:

Improvement in cultivation efficiency

Supports 24/7 fully automatic operation, increasing efficiency by 25 times
Adopting a unified software platform, it is easy to operate and reduces reliance on automation equipment debugging and professional programmers

Standardization and repeatability improvement

Automated operation throughout the entire process, effectively avoiding human errors
The validated experimental protocol is applicable to multiple types of organs, including the intestine, forebrain, midbrain, heart, liver, etc
Equipped with deep learning artificial intelligence software to achieve automatic quality control and intelligent decision-making in the cultivation process

Industrialization Achievements: Sharing of Successful Cases

Since its launch, CellXpress.ai has accumulated a wealth of successful cases. Here are several representative case studies shared.

Organoids derived from primary tissue sources

Toxicity screening of gut organoid compounds in healthy individuals based on artificial intelligence.The damage of anticancer drugs to intestinal cells is one of the most common and dose limiting side effects of chemotherapy, often limiting the effectiveness of treatment. In this study, a compound intestinal toxicity automated assessment platform based on human intestinal organoids was successfully constructed. The platform uses CellXpress.ai and high content ImageXpress HCS.ai to achieve full automation of human intestinal organoid culture, compound addition, and staining processes. In compound testing, organoids were evaluated by exposure to eight drugs known to have intestinal toxicity.

Fully automated workflow for drug screening of human intestinal organoids (HIOs): The CellXpress.ai system is used to inoculate the HIOs onto a 96 well U-plate, monitored every 24 hours through transmitted light imaging, and treated with anti-cancer compounds on the second day. On the 5th day after vaccination, live cell imaging was performed using the ImageXpress HCS.ai system (endpoint analysis was performed using IN Carta software for AI driven phenotype analysis)

CellXpress.ai monitoring example: Display of human intestinal organoids cultured in a 96 well U-shaped baseplate, imaged using a bright field microscope (TL)

Detection of organoid phenotype response after 72 hours of compound treatment using ImageXpress HCS.ai high content system

Swipe left and right to view more

Click to download relevant materials

IPSC induced organoids

Due to its abundant sources, personalized preparation, and ethical advantages, it has become a focus of the industry. The CellXpress.ai system has been successfully validated for large-scale cultivation and functional testing of iPSC induced organoids. This study focuses on the functional characterization of spontaneous calcium oscillations in iPSC derived 3D neural organs and the evaluation of neuroactive compounds.

Schematic diagram of experimental process.(1-4) Preparation and differentiation of organoids: STEMCEL Technologies series products (inoculum, formation medium, expansion medium, and differentiation medium) are used to selectively differentiate human pluripotent stem cells into organoids; (5) Organoid maintenance culture (6) detection and imaging analysis: completed using Molecular Devices FLIPR Penta high-throughput detection system and ImageXpress Micro confocal system

Preparation process of human dorsal forebrain and midbrain organoids

Schematic diagram of CellXpress.ai in vitro model automated factory. Microscopic images of neural organs cultured in 96 well plates

Analysis of baseline calcium oscillations and drug response characteristics in dorsal forebrain organoids.The dynamic calcium imaging technique of FLIPR Penta system was used to record Ca2+fluctuation signals, and Peak Pro 2 software was used for analysis. The results showed that (left figure) without the addition of compounds, the organoids exhibited stable basal electrophysiological activity; After adding the specified compound (shown as 0.4 μ M concentration, with a total of 4 dose gradients tested), the calcium oscillation mode underwent specific changes

Swipe left and right to view more

Click to download relevant materials

Cell spheres co cultured with multiple cells

Automated cultivation and functional analysis of 3D three cell co cultured cardiac cell spheres derived from human iPSC.Constructing a human tissue model using induced pluripotent stem cell (iPSC) derived cell types is a promising new strategy for accelerating drug development and safety/toxicity assessment. By co culturing iPSC derived cardiomyocytes (CM), iPSC derived endothelial cells (EC), and iPSC derived cardiac fibroblasts (CF) into a cardiac cell sphere model, CellXpress.ai was used to automate the entire process of cell sphere formation and maintenance, demonstrating significant potential for application in compound efficacy evaluation and early detection of cardiac toxicity.

CellXpress.ai system running instance. (A) The display system performs medium replacement operation in a 384 well plate. (B) Bright field images of iPSC derived 3D three cell co cultured cardiac spheres in a 96 well plate. (C) Implement automatic segmentation and quantitative analysis during 3D cultivation process through custom module editor (CME)

(A) Use the CellXpress.ai system to image cardiac microstructures stained with Calcium 6 dye for FLIPR detection. (B) Display the optimal focal length projection image (10x) of cells stained with cell reactive dyes, including Hoechst (blue), Calcein AM (green), and EtHD (red). Treat cells with cardiotoxic compounds, including 100 μ M doxorubicin and 10 μ M erythromycin. Image analysis evaluated the cell sphere area and average intensity of different fluorescent groups. Cell activity can be presented by the standardized ratio of the average fluorescence intensity of live/dead cells

Use 3D cell spheres for calcium detection. Calcium oscillations (concentration unit: μ M) measured after treating 3D cardiac cell spheres with various compounds. Use the FLIPR Penta system to record Ca2+waveforms through dynamic calcium imaging and analyze them using Peak Pro 2 software. After adding the specified compound, the representative trajectory displays a waveform pattern that is significantly different from the control signal. Evaluated peak frequency, amplitude, peak extension, and other measurement values for different compounds and concentrations

Swipe left and right to view more

Click to download relevant materials

Conclusion

On the path of industrialization of organoids, choosing validated solutions is far more important than chasing concepts. CellXpress.ai has proven the feasibility of AI supported automated organoid culture technology through more than a year of practical experience with dozens of users.

We offer testing opportunities, welcome to make an appointment on the platform to experience!

Exciting pause, unfinished yet to be continued. The next issue is being prepared intensively, and we sincerely invite you to continue following us.

Related product links:

CellXpress.ai in vitro model intelligent factory

About Meigu Molecular Instrument

Molecular Devices was founded in Silicon Valley, USA in the 1980s and has multiple representative offices and subsidiaries worldwide. In 2005, Molecular Devices established a representative office in Shanghai, joined Danaher Group, a global innovator in science and technology, in 2010, and officially established a business company in 2011: Meigu Molecular Instruments (Shanghai) Co., Ltd. Molecular Devices is renowned in the industry for its continuous innovation, fast, efficient, high-performance products, and comprehensive after-sales service. We have been committed to providing customers with innovative biological analysis solutions in protein and cell biology in the fields of life science research, pharmaceutical and biological therapy development.

Last Article: Biosensor exploration leads to increased production of L-threonine in Escherichia coli

Next Article: Species specific proteins - protein-protein interactions control humanization of yeast 20S proteasome